Search for a trial

BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age

To evaluate the safety and efficacy of BOTOX for the treatment of urinary incontinencedue to overactive bladder (OAB) in patients 12 to 17 years of age who have not been adequately managed with anticholinergic therapy. To evaluate the safety and…

Urostoma APPtimize: Improving quality of life of patients having a urostomy by offering personalised and timed guidance and peer-contact in a patient-centred mobile application

The main objective of this study is to investigate whether quality of life can be improved by personalised and timed guidance, and/or use of the peer-support platform; as provided by a patient-centred mobile application.

A randomized, placebo-controlled three-way cross-over study to compare the pulsatile intravaginal delivery of oxybutynin versus oral administration.

Primary• To compare the anticholinergic side effects between repeated intravaginal administration of oxybutynin with the vaginal MedRing device and repeated oral administrationSecondary• To explore the pharmacokinetics of oxybutynin and its main…

GAG-therapy Efficacy Trial Solution for Bladder pain syndrome/ Interstitial cystitis

Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain. Secondary objectives are to determine the 1) cost-…

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2a, Proof-of-Concept Study of ASP8302 in Subjects with Underactive Bladder

•To evaluate the efficacy of ASP8302 compared with placebo in subjects with Underactive Bladder (UAB)•To investigate the safety and tolerability of ASP8302 compared with placebo in subjects with UAB•To investigate the pharmacokinetics of ASP8302 in…

A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjects from 5 to < 18 Years of Age with Overactive Bladder

ObjectivesPrimary* To evaluate the efficacy of mirabegron in children (5 to < 18 years of age) with OABSecondary* To evaluate the efficacy of mirabegron in children (5 to < 18 years of age) with OAB* To evaluate the safety and…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.

The primary objective of this study is to compare the progression-free survival (PFS) of ramucirumab in combination with docetaxel with the PFS of placebo in combination with docetaxel, in patients with locally advanced or unresectable or metastatic…

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

This study has been transitioned to CTIS with ID 2023-503500-87-00 check the CTIS register for the current data. This study is designed to assess the antitumor efficacy and safety of pembrolizumab + CRT following maximal TURBT compared with placebo…

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

This study has been transitioned to CTIS with ID 2022-500630-29-00 check the CTIS register for the current data. We hypothesise that treatment with nivolumab will extend disease-free survival, compared with placebo, as adjuvant therapy in all…

Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?

Improves the alpha blocker Silodosin the bladder emptying in patients with MS? Improves the alpha blocker Silodosin the quality of life of patients with MS?

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis

To investigate efficacy of ASP6294 in female subjects with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).To investigate safety and tolerability of ASP6294 in female subjects with BPS/IC.To investigate the pharmacokinetics and pharmacodynamics…

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Primary ObjectiveThe primary objective of this study is to evaluate the effect of 12 weeks of treatment with 2 different doses of oral AQX-1125 (100 mg or 200 mg) administered once daily compared to placebo on the change from Baseline (Visit 2) to…